Form 4: Cytek Biosciences CEO Wenbin Jiang Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Cytek Biosciences' CEO, Wenbin Jiang, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

  • On February 18, 2025, Wenbin Jiang, the CEO of Cytek Biosciences, exercised 6,758 Restricted Stock Units (RSUs).
  • These RSUs converted into common stock.
  • 2,004 shares were withheld by Cytek Biosciences to cover tax obligations at a price of $5.31 per share.
  • Following these transactions, Jiang directly owns 5,192,392 shares of Cytek Biosciences common stock and 24,788 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard reporting of insider transactions related to stock-based compensation.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency to investors regarding the holdings and transactions of company insiders.

Stakeholder Impact

  • The transaction has a minor impact on shareholders as it reflects the CEO's compensation and ownership stake in the company.

Key Dates

DateDescription
May 18, 2022Initial vesting date of the RSU Award, with 4/48th of the total shares vesting.
August 18, November 18, February 18, May 18 (subsequent quarters)Subsequent quarterly vesting dates of the RSU Award, with 3/48th of the total shares vesting each quarter.
02/18/2025Date of the reported transactions: RSU exercise and tax withholding.
02/20/2025Date of the Form 4 filing.

Keywords

Cytek Biosciences, CTKB, Wenbin Jiang, Form 4, Stock transaction, Restricted Stock Units, RSU, Insider trading, Beneficial ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.